Semin Respir Crit Care Med 2000; 21(1): 0033-0044
DOI: 10.1055/s-2000-9930
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Antibiotic Resistance in Community-Acquired Pulmonary Pathogens

Franco Paradisi, Giampaolo Corti
  • Infectious Disease Unit, University of Florence School of Medicine Careggi Hospital, Florence, Italy
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Dezember 2000 (online)

 

ABSTRACT

Among infectious diseases, pneumonia is still the ``captain of the men of death.'' Etiologic diagnosis is often unreliable; consequently, clinicians must know epidemiology of community-acquired pneumonia for optimizing empiric antibiotic therapy. In recent years, all major pulmonary pathogens have become more and more resistant to conventional antibiotics. Penicillin-resistant and even multiresistant pneumococci have spread worldwide, but primarily in the United States, some European countries, South Africa, and the Far East. A similar trend is evidenced by ampicillin-resistant Hemophilus influenzae, whereas Moraxella catarrhalis almost invariably produces β-lactamases. The widening of methicillin-resistant Staphylococcus aureus from hospitals to the community may be the new reality of the 1990s. Increasing erythromycin resistance of Streptococcus pyogenes requires β-lactam therapy. The spread of both cromosomally and plasmid-mediated β-lactamases makes treatment of infections caused by gram-negative enterobacilli more difficult. Bacterial resistance creates a challenge for clinicians from the viewpoint of correct and successful management of patients with community-acquired pneumonia.

KEYWORD

Antibiotic resistance - community-acquired - lower respiratory tract infection

REFERENCES

  • 1 Osler W. The Principles and Practice of Medicine.  4th ed. New York: Appleton and Co. 1901
    Google Scholar
  • 2 Pinner R W, Teutsch S M, Simonsen L. Trends in infectious diseases mortality in the United States.  JAMA . 1996;  275 189-193
    CrossrefPubMedGoogle Scholar
  • 3 Campbell G D. Overview of community-acquired pneumonia: Prognosis and clinical features.  Med Clin North Am . 1994;  78 1035-1048
    PubMedGoogle Scholar
  • 4 Fine M J, Auble T E, Yealy D M. A prediction rule to identify low-risk patients with community-acquired pneumonia.  N Engl J Med . 1997;  336 243-250
    CrossrefPubMedGoogle Scholar
  • 5 Fine M J, Smith M A, Carson C A. Prognosis and outcomes of patients with community-acquired pneumonia: A meta-analysis.  JAMA . 1996;  275 134-141
    CrossrefPubMedGoogle Scholar
  • 6 Bartlett J G, Breiman R F, Mandell L A, File Jr M T. Community-acquired pneumonia in adults: Guidelines for management.  Clin Infect Dis . 1998;  26 811-838
    CrossrefPubMedGoogle Scholar
  • 7 Washington J A. Noninvasive diagnostic techniques for lower respiratory infections. In: Pennington JE, ed. Respiratory Infections: Diagnosis and Management, 3rd ed New York: Raven Press, Ltd., 1994: 55-71
    Google Scholar
  • 8 Bartlett J G, Mundy L M. Community-acquired pneumonia.  N Engl J Med . 1995;  333 1618-1624
    CrossrefPubMedGoogle Scholar
  • 9 Bartlett J G. Invasive diagnostic techniques in pulmonary infections. In: Pennington JE, ed. Respiratory Infections: Diagnosis and Management, 3rd ed New York: Raven Press, Ltd., 1994: 73-99
    Google Scholar
  • 10 Mandell L A. Community-acquired pneumonia: Etiology, epidemiology, and treatment.  Chest . 1995;  108 35S-42S
    PubMedGoogle Scholar
  • 11 Bullowa J GM. The reliability of sputum typing and its relation to serum therapy.  JAMA . 1935;  105 1512-1518
    PubMedGoogle Scholar
  • 12 MacFarlane J. An overview of community-acquired pneumonia with lessons from the British Thoracic Society Study.  Semin Respir Infect . 1994;  9 153-165
    PubMedGoogle Scholar
  • 13 Bariffi F, Sanduzzi A, Ponticiello A. Epidemiology of lower respiratory tract infections.  J Chemother . 1995;  7 263-276
    PubMedGoogle Scholar
  • 14 Niederman M S, Bass Jr B J, Campbell G D. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy.  Am Rev Respir Dis . 1993;  148 1418-1426
    CrossrefPubMedGoogle Scholar
  • 15 Mandell L A, Niederman M, the Canadian Community-Acquired Pneumonia Consensus Conference Group. Antimicrobial treatment of community-acquired pneumonia in adults: A conference report.  Can J Infect Dis . 1993;  4 25-28
    PubMedGoogle Scholar
  • 16 The British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital.  Br J Hosp Med . 1993;  49 346-350
    PubMedGoogle Scholar
  • 17 Örtqvist Å. Antibiotic treatment of community-acquired pneumonia in clinical practice: A European perspective.  J Antimicrob Chemother . 1995;  35 205-212
    PubMedGoogle Scholar
  • 18 Del Castillo F, Baquero-Artigao F, Garcia-Perea A. Influence of recent antibiotic therapy on antimicrobial resistance of Streptococcus pneumoniae in children with acute otitis media in Spain.  Pediatr Infect Dis J . 1998;  17 94-97
    CrossrefPubMedGoogle Scholar
  • 19 Gonzales R, Steiner J F, Sande M A. Antibiotics prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory physicians.  JAMA . 1997;  278 901-904
    CrossrefPubMedGoogle Scholar
  • 20 Schwartz B, Bell D M, Hughes J M. Preventing the emergence of antimicrobial resistance: A call for action by clinicians, public health officials, and patients.  JAMA . 1997;  278 944-945
    CrossrefPubMedGoogle Scholar
  • 21 National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 7th informational supplement (M100-S7) Villanova: National Committee for Clinical Laboratory Standards 1997
  • 22 Grebe T, Hakenbeck R. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics.  Antimicrob Agents Chemother . 1996;  40 829-834
    PubMedGoogle Scholar
  • 23 Smith A M, Klugman K P. Alterations in PBP1a essential for for high-level penicillin resistance in pneumococci. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington: American Society for Microbiology, Toronto, Canada, September 28-October 1, 1997; Abstract C174
    Google Scholar
  • 24 Coffey T J, Dowson C G, Daniels M, Spratt B. Genetics and molecular biology of beta-lactam-resistant pneumococci.  Microb Drug Resist . 1995;  1 29-34
    PubMedGoogle Scholar
  • 25 Soares S, Kristinsson K G, Musser J M, Tomasz A. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s.  J Infect Dis . 1993;  168 158-163
    PubMedGoogle Scholar
  • 26 Muñoz R, Coffey T J, Daniels M. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae J Infect Dis .  1991;  164 302-306
    PubMedGoogle Scholar
  • 27 Tomasz A. The pneumococcus at the gates.  N Engl J Med . 1995;  33 514-515
    PubMedGoogle Scholar
  • 28 Baquero F. Trends in antibiotic resistance of respiratory pathogens: An analysis and commentary on a collaborative surveillance study.  J Antimicrob Chemother . 1996;  38(suppl A) 117-132
    PubMedGoogle Scholar
  • 29 Tomasz A. Antibiotic resistance in Streptococcus pneumoniae Clin Infect Dis .  1997;  24(suppl 1) S85-S88
    PubMedGoogle Scholar
  • 30 Gold H S, Moellering Jr C R. Antimicrobial-drug resistance.  N Engl J Med . 1996;  335 1445-1453
    CrossrefPubMedGoogle Scholar
  • 31 Baquero F, Cantón R, Baquero-Artigao F. Current patterns and evolution of antibiotic resistance among bacterial pathogens involved in acute otitis media.  Clin Microbiol Infect . 1997;  3(suppl 3) S26-S33
    PubMedGoogle Scholar
  • 32 Klugman K P. Pneumococcal resistance to antibiotics.  Clin Microbiol Rev . 1990;  3 171-196
    PubMedGoogle Scholar
  • 33 Hansman D, Bullen M M. A resistant pneumococcus.  Lancet . 1967;  264-265
    PubMedGoogle Scholar
  • 34 Jacobs M R, Koornhof H J, Robins-Browne R M. Emergence of multiply resistant pneumococci.  N Engl J Med . 1978;  299 735-740
    CrossrefPubMedGoogle Scholar
  • 35 Grüneberg R N, Felmingham D, the Alexander Project Group. Results of the Alexander Project: A continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens.  Diagn Microbiol Infect Dis . 1996;  25 169-181
    CrossrefPubMedGoogle Scholar
  • 36 Jacobs M R, Dagan R, Appelbaum P C, Burch D J. Prevalence of antimicrobial-resistant pathogens in middle ear fluid: Multinational study of 917 children with acute otitis media.  Antimicrob Agents Chemother . 1998;  42 589-595
    PubMedGoogle Scholar
  • 37 Doern G V. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract.  Am J Med . 1995;  99(suppl 6B) 3S-7S
    CrossrefPubMedGoogle Scholar
  • 38 Washington J A, the Alexander Project Group. A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992-1994; The Alexander Project.  Diagn Microbiol Infect Dis . 1996;  25 183-190
    CrossrefPubMedGoogle Scholar
  • 39 Doern G V, Brueggemann A, Holley Jr P H, Rauch A M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995; Results of a 30-center national surveillance study.  Antimicrob Agents Chemother . 1996;  40 1208-1213
    PubMedGoogle Scholar
  • 40 Thornsberry C, Ogilvie P, Kahn J, Mauriz Y, the Laboratory Investigator Group. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season.  Diagn Microbiol Infect Dis . 1997;  29 249-257
    CrossrefPubMedGoogle Scholar
  • 41 Baquero F, Barrett J F, Courvalin P, Morrissey I, Piddock L, Novick W J. Epidemiology and mechanisms of resistance among respiratory tract pathogens.  Clin Microbiol Infect . 1998;  4(suppl 2) S19-S26
    PubMedGoogle Scholar
  • 42 Bedos J P, Chevret S, Chastang C, Geslin P, Régnier B, French Cooperative Pneumococcus Study Group. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: Findings of a French survey.  Clin Infect Dis . 1996;  22 63-72
    PubMedGoogle Scholar
  • 43 Lee H J, Park J Y, Jang S H, Kim J H, Kim E C, Choi K W. High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea.  Clin Infect Dis . 1995;  20 826-835
    PubMedGoogle Scholar
  • 44 Pallares R, Liñares J, Vadillo M. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.  N Engl J Med . 1995;  333 474-480
    CrossrefPubMedGoogle Scholar
  • 45 Martínez-Martínez L, López-Hernández I, Pascual A, Suárez A I, Perea E J. Resistance of Streptococcus pneumoniae to penicillin, erythromycin and third-generation cephalosporins in Seville, Southern Spain.  Clin Microbiol Infect . 1997;  3 382-385
    PubMedGoogle Scholar
  • 46 Butler J C, Hofmann J, Cetron M S. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: An update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System.  J Infect Dis . 1996;  174 986-993
    PubMedGoogle Scholar
  • 47 Jacoby G A. Prevalence and resistance mechanisms of common bacterial respiratory pathogens.  Clin Infect Dis . 1994;  18 951-957
    PubMedGoogle Scholar
  • 48 Janoir C, Zeller V, Kitzis M-D, Moreau N J, Gutmann L. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA Antimicrob Agents Chemother .  1996;  40 2760-2764
    PubMedGoogle Scholar
  • 49 Visalli M A, Jacobs M R, Appelbaum P C. Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.  Antimicrob Agents Chemother . 1997;  41 1867-1870
    PubMedGoogle Scholar
  • 50 Marchese A, Debbia E, Pesce A, Schito G C. Comparative activities of amoxycillin and 10 other oral drugs against penicillin-susceptible and -resistant Streptococcus pneumoniae strains recently isolated in Italy.  Clin Microbiol Infect . 1998;  4 170-173
    PubMedGoogle Scholar
  • 51 Goldstein F, Bryskier A, Appelbaum P C. The etiology of respiratory tract infections and the antibacterial activity of fluoroquinolones and other oral antibacterial agents against respiratory pathogens.  Clin Microbiol Infect . 1998;  4(suppl 2) S8-S18
    PubMedGoogle Scholar
  • 52 Pankuch G A, Jacobs M R, Appelbaum P C. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci.  J Antimicrob Chemother . 1995;  35 230-232
    PubMedGoogle Scholar
  • 53 Segal-Maurer S, Urban C, Rahal Jr J J. Current perspectives on multidrug-resistant bacteria: Epidemiology and control.  Infect Dis Clin North Am . 1996;  10 939-957
    CrossrefPubMedGoogle Scholar
  • 54 Rubinstein E, Carbon C C, Rangaraj M, Santos J I, Thys J-P, Veyssier P. Lower respiratory tract infections: Etiology, current treatment, and experience with fluoroquinolones.  Clin Microbiol Infect . 1998;  4(suppl 2) S42-S50
    PubMedGoogle Scholar
  • 55 Leggiadro R J. The clinical impact of resistance in the management of pneumococcal disease.  Infect Dis Clin North Am . 1997;  11 867-874
    CrossrefPubMedGoogle Scholar
  • 56 Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance.  Infect Control Hosp Epidemiol . 1995;  16 106-113
    PubMedGoogle Scholar
  • 57 Bouanchaud D H. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.  J Antimicrob Chemother . 1997;  39(suppl A) 15-21
    PubMedGoogle Scholar
  • 58 Jernigan D B, Cetron M S, Breiman R F. Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP): A strategy from the DRSP Working Group.  JAMA . 1996;  275 206-209
    CrossrefPubMedGoogle Scholar
  • 59 Centers for Disease Control and Prevention. Defining the public health impact of drug-resistant Streptococcus pneumoniae: Report of a working group.  MMWR Morb Mortal Wkly Rep . 1996;  45(RR-1) 1-20
    PubMedGoogle Scholar
  • 60 Gonzales R, Steiner J F, Sande M A. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory physicians.  JAMA . 1997;  278 901-904
    CrossrefPubMedGoogle Scholar
  • 61 Kristinsson K G, Hjálmarsdóttir M A, Gudnason T. Epidemiology of penicillin-resistant pneumococci (PRP) in Iceland-hope for the future?. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995; Washington: American Society for Microbiology, Abstract C9
    Google Scholar
  • 62 Centers for Disease Control and Prevention. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practice (ACIP).  MMWR Morb Mortal Wkly Rep . 1997;  46(RR-8) 1-24
    PubMedGoogle Scholar
  • 63 Public Health Service. Healthy people 2000; National health promotion and disease prevention objectives. Washington: Department of Health and Human Services, 1991; DHHS publication PHS 91-50212
  • 64 Centers for Disease Control and Prevention. Pneumococcal and influenza vaccination levels among adults aged ≥65 years-United States, 1993.  MMWR Morb Mortal Wkly Rep . 1996;  45 853-859
    PubMedGoogle Scholar
  • 65 Centers for Disease Control and Prevention. Pneumococcal and influenza vaccination levels among adults aged ≥65 years-United States, 1995.  MMWR Morb Mortal Wkly Rep . 1997;  46 913-919
    PubMedGoogle Scholar
  • 66 Klein D L. Pneumococcal conjugate vaccines: Review and update.  Microb Drug Resist . 1995;  1 49-58
    PubMedGoogle Scholar
  • 67 Doern G V, Brueggemann A B, Pierce G, Holley Jr P H, Rauch A. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study.  Antimicrob Agents Chemother . 1997;  41 292-297
    PubMedGoogle Scholar
  • 68 Jones R N, Jacobs M R, Washington J A, Pfaller M A. A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States.  Diagn Microbiol Infect Dis . 1997;  27 75-83
    CrossrefPubMedGoogle Scholar
  • 69 Campos J, Roman F, Georgiou M. Long term persistence of ciprofloxacin-resistant H. influenzae in patients with cystic fibrosis.  J Infect Dis . 1996;  174 1345-1347
    PubMedGoogle Scholar
  • 70 Dowell S F, Marcy S M, Phillips W R, Gerber M A, Schwartz B. Otitis media-Principles of judicious use of antimicrobial agents.  Pediatrics . 1998;  101(suppl) 165-171
    PubMedGoogle Scholar
  • 71 Schito G C, Debbia E A, Pesce A, Alexander Project Collaborative Group. Susceptibility of respiratory strains of Staphylococcus aureus to fifteen antibiotics: Results of a collaborative surveillance study (1992-1993).  J Antimicrob Chemother . 1996;  38(suppl A) 97-106
    PubMedGoogle Scholar
  • 72 Voss A, Kresken M. Antibiotic resistance in staphylococci in Europe.  Chemotherapy . 1996;  42(suppl 2) 13-18
    PubMedGoogle Scholar
  • 73 Coronado V G, Edwards J R, Culver D H, Gaynes R P, the National Nosocomial Infection Surveillance System. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States.  Infect Control Hosp Epidemiol . 1995;  16 71-75
    PubMedGoogle Scholar
  • 74 Utili R, Tripodi M F, Rosario P. Different susceptibility of coagulase-positive and coagulase-negative staphylococci to ciprofloxacin.  New Microbiol . 1996;  19 309-314
    PubMedGoogle Scholar
  • 75 National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System.  Am J Infect Control . 1996;  24 380-388
    CrossrefPubMedGoogle Scholar
  • 76 Rosenberg J. Methicillin-resistant Staphylococcus aureus (MRSA) in the community: Who's watching?.  Lancet . 1995;  346 132-133
    PubMedGoogle Scholar
  • 77 Johnston B L. Methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia-A critical review.  Semin Respir Infect . 1994;  9 199-206
    PubMedGoogle Scholar
  • 78 Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover F C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.  J Antimicrob Chemother . 1997;  40 135-136
    CrossrefPubMedGoogle Scholar
  • 79 Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997.  MMWR Morb Mortal Wkly Rep . 1997;  46 813-815
    PubMedGoogle Scholar
  • 80 Ploy M C, Grélaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital.  Lancet . 1998;  351 1212
    PubMedGoogle Scholar
  • 81 Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: A common pattern mediated by an efflux system.  Antimicrob Agents Chemother . 1996;  40 1817-1824
    PubMedGoogle Scholar
  • 82 Coonan K M, Kaplan E M. In vitro susceptibility of recent North American group A streptococcal isolates to eleven oral antibiotics.  Pediatr Infect Dis J . 1994;  13 630-635
    CrossrefPubMedGoogle Scholar
  • 83 Hsueh P R, Chen H M, Huang A H, Wu J J. Decreased activity of erythromycin against Streptococcus pyogenes in Taiwan.  Antimicrob Agents Chemother . 1995;  39 2239-2242
    PubMedGoogle Scholar
  • 84 Cornaglia G, Ligozzi M, Mazzariol A. Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995.  Emerg Infect Dis . 1996;  2 339-342
    PubMedGoogle Scholar
  • 85 Cocuzza C, Blandino G, Mattina R, Nicoletti F, Nicoletti G. Antibiotic susceptibility of group A streptococci in 2 Italian cities: Milano and Catania.  Microb Drug Resist . 1997;  3 379-384
    PubMedGoogle Scholar
  • 86 Cocuzza C E, Mattina R, Mazzariol A. High incidence of erythromycin-resistant Streptococcus pyogenes in Monza (North Italy) in untreated children with symptoms of acute pharyngotonsillitis: An epidemiological and molecular study.  Microb Drug Resist . 1997;  3 371-378
    PubMedGoogle Scholar
  • 87 Swartz M N. Use of antimicrobial agents and drug resistance.  N Engl J Med . 1997;  337 491-492
    CrossrefPubMedGoogle Scholar
  • 88 Sanders C CC, Sanders Jr E W. Type I beta-lactamases of gram-negative bacteria: Interactions with beta-lactam antibiotics.  J Infect Dis . 1986;  154 792-800
    PubMedGoogle Scholar
  • 89 Knothe H, Shah P, Krcméry V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens Infection .  1983;  11 315-317
    CrossrefPubMedGoogle Scholar
  • 90 Jones R N, Kehrberg E N, Erwin M E, Anderson S C, Fluoroquinolone Resistance Surveillance Group. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistance: Real or perceived?.  Diagn Microbiol Infect Dis . 1994;  19 203-215
    CrossrefPubMedGoogle Scholar
  • 91 Jones R N, Baquero F, Privitera G, Inoue M, Wiedemann B. Inducible beta-lactamase-mediated resistance to third-generation cephalosporins.  Clin Microbiol Infect . 1997;  3(suppl 1) S7-S20
    PubMedGoogle Scholar
  • 92 Jacobson K L, Cohen S H, Inciardi J F. The relationship between antecedent use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms.  Clin Infect Dis . 1995;  21 1107-1113
    PubMedGoogle Scholar
  • 93 Du Bois K S, Marriott M S, Amyes S GB. TEM- and SHV-derived extended-spectrum beta-lactamases: Relationship between selection, structure and function.  J Antimicrob Chemother . 1995;  35 7-22
    CrossrefPubMedGoogle Scholar
  • 94 Livermore D M, Yuan M. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.  J Antimicrob Chemother . 1996;  38 409-424
    PubMedGoogle Scholar
  • 95 Chen H Y, Yuan M, Ibrahim-Elmagboul I B, Livermore D M. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa J Antimicrob Chemother .  1995;  35 521-534
    PubMedGoogle Scholar
  • 96 Troillet N, Samore M H, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: Risk factors and antibiotic susceptibility patterns.  Clin Infect Dis . 1997;  25 1094-1098
    PubMedGoogle Scholar
  • 97 Casellas J M, Blanco M G, Pinto M E. The sleeping giant. Antimicrobial resistance.  Infect Dis Clin North Am . 1994;  8 29-45
    PubMedGoogle Scholar
  • 98 Acar J F, Goldstein F W. Trends in bacterial resistance to fluoroquinolones.  Clin Infect Dis . 1997;  24(suppl 1) S67-S73
    PubMedGoogle Scholar
  • 99 Kresken M, Hafner D, Mittenmayer H. Prevalence of fluoroquinolone resistance in Europe.  Infection . 1994;  22(suppl 2) 90-98
    CrossrefPubMedGoogle Scholar
  • 100 Prosser B L, Beskid G. Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.  Diagn Microbiol Infect Dis . 1995;  21 33-45
    CrossrefPubMedGoogle Scholar
  • 101 Turnidge J. Epidemiology of quinolone resistance: Eastern hemisphere.  Drugs . 1995;  49(suppl 2) 43-47
    PubMedGoogle Scholar
  • 102 Corti G, Paradisi F, Giganti E. Ciprofloxacin resistance in clinical isolates of Pseudomonas aeruginosa from Italian patients.  Drugs . 1995;  49(suppl 2) 175-176
    PubMedGoogle Scholar
      >